Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Testicular Neoplasms

Seminoma

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Germinoma

Endocrine Gland Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Male Urogenital Diseases

Endocrine System Diseases

Testicular Diseases

Gonadal Disorders

Germ Cells Tumors

Testicular Seminoma

Central Nervous System Germinoma

Patients undergo collection of blood every 3-6 months for up to 3 years.

Biomarker Analysis

Blood Product Collection

Patricia O'Kane

Dana Sparks, MAT

Site Public Contact

Isaac A. Bowman

John A. Ellerton

Edward P. Gelmann

Jay W. Carlson

Helen H. Moon

Andrea L. Harzstark

Siamak Daneshmand

Lisa Bailey

Frederick E. Millard

Brian R. Hu

Mark S. Litwin

Arash Rezazadeh Kalebasty

Nicholas G. Cost

Gregory A. Masters

Jeffrey L. Berenberg

Craig R Nichols

This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.

PRIMARY OBJECTIVE:

I. To estimate the positive predictive value within each of the early stage testicular seminoma and nonseminoma groups using plasma miRNA 371 expression at relapse to detect germ cell malignancy.

SECONDARY OBJECTIVES:

I. To bank prospectively obtained serial liquid biospecimens for low and moderate risk of relapse patients annotated by patient level clinical data.

II. To bank prospectively collected, clinically annotated specimens for high risk patients and non-testicular primary patients in collaboration with Children's Oncology Group study AGCT 1531.

OUTLINE:

Patients undergo collection of blood every 3-6 months for up to 3 years.

A Study of miRNA 371 in Patients With Germ Cell Tumors

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

Positive predictive value will be estimated using plasma miRNA 371 expression at relapse.

10 ml whole blood will be collected at time points specified by the protocol.

National Cancer Institute (NCI)

SWOG Cancer Research Network

Spots Global Cancer Trial Database for blood product collection